2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
2
Rare Diseases
across 5 areas
0
News (30d)
Quiet
EydisBio, Inc. is a company with 2 orphan drug designations across 2 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| malignant glioma | 5,6-dimethyl-N-[1-(phenylmethyl)-3-pyrrolidinyl]-thieno[2,3-d]pyrimidin-4-amine, monobenzenesulfonate | Des.TrialAppr. |
| systemic sclerosis | (E)-N-(6-(piperidin-1-ylmethyl)-1-propyl-1,3-dihydro-2H-benzo[d]imidazol-2-ylidene)isophthalamide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio